Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 3/2011

01.07.2011 | Review

Intravenous Thrombolytics for Ischemic Stroke

verfasst von: Andrew D. Barreto

Erschienen in: Neurotherapeutics | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

For many decades, intravenous (IV) thrombolytics have been delivered to treat acute thrombosis. Although these medications were originally effective for coronary thrombosis, their mechanisms have proven beneficial for many other disease processes, including ischemic stroke. Treatment paradigms for acute ischemic stroke have largely followed those of cardiology. Specifically, the aim has been to recanalize the occluded artery and to restore perfusion to the brain that remains salvageable. To that end, rapid clot lysis was sought using thrombolytic medicines already proven effective in the coronary arteries. IV-thrombolysis for ischemic stroke began its widespread adoption in the late 1990s after the publication of the National Institute of Neurological Disorders and Stroke study. Since that time, other promising IV-thrombolytics have been developed and tested in human trials, but as of yet, none have been proven better than a placebo. Adjunctive treatments are also being evaluated. The challenge remains balancing reperfusion and salvaging brain tissue with the potential risks of brain hemorrhage.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Mackay JMG. The atlas of heart disease and stroke. London: World Stroke Organization; 2004.
2.
Asplund KSB, Peltonem M. From the twentieth to the twenty-first century: a public health perspective on stroke. In: Ginsberg MD, ed. Cerebrovascular Disease Pathophysiology, Diagnosis and Management. Malden, Mass: Blackwell Science; 1998.
3.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation121:e46-e215.
4.
Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645–2657.PubMed
5.
Colman RW, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2006.
6.
Loren M, Garcia Frade LJ, Torrado MC, Navarro JL. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res 1989;56:67–75.PubMedCrossRef
7.
Collen D. On the regulation and control of fibrinolysis. Edward Kowalski memorial lecture. Thromb Haemost 1980;43:77–89.PubMed
8.
Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485–502.PubMedCrossRef
9.
Christensen LR, Macleod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945;28:559–583.PubMedCrossRef
10.
Johnson AJ, Tillett WS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952;95:449–464.PubMedCrossRef
11.
Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958;71:287–296.PubMed
12.
Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987;33:77–86.PubMedCrossRef
13.
Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther 2009;9:773–778.PubMedCrossRef
14.
Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. The maintenance of a sustained thrombolytic state in man. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959;38:1111–1119.PubMedCrossRef
15.
Schmutzler R, Heckner F, Kortge P, et al. Thrombolytic therapy of recent myocardial infarction. I. Introduction, plan of trial, general clinical results. Ger Med Mon 1966;11:308–314.PubMed
16.
Bett JHN, Castaldi PA, Hale GS, et al. Australian multicentre trial of streptokinase in acute myocardial infarction. Lancet 1973;301:57–60.CrossRef
17.
Aber CP, Bass NM, Berry CL, et al. Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom. Br Med J 1976;2:1100–1104.PubMedCrossRef
18.
Dioguardi N, Lotto A, Levi GF, et al. Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet 1971;2:891–895.PubMedCrossRef
19.
Streptokinase in acute myocardial infarction. European Cooperative Study Group for streptokinase treatment in acute myocardial infarction. N Engl J Med 1979;301:797–802.
20.
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). Lancet 1986;327:397–402.
21.
GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. Lancet 1990;336:65–71.
22.
ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (third international study of infarct survival) collaborative group. Lancet 1992;339:753–770.
23.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673–682.
24.
Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for coronary artery bypass graft surgery). J Am Coll Cardiol 2004;44:e213-e310PubMedCrossRef
25.
Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc 1958;167:1705–1709.PubMed
26.
Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963;13:927–937.PubMed
27.
Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964;189:373.PubMed
28.
Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135–142.PubMedCrossRef
29.
del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988;19:307–313.PubMedCrossRef
30.
Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216–1222.PubMedCrossRef
31.
Thrombolytic therapy in thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980;93:141–144.
32.
Thrombolytic therapy with streptokinase in acute ischemic stroke. The multicenter acute stroke trial — Europe study group. N Engl J Med 1996;335:145–150.
33.
Crowell RM, Marcoux FW, DeGirolami U. Variability and reversibility of focal cerebral ischemia in unanesthetized monkeys. Neurology 1981;31:1295–1302.PubMed
34.
Zeumer H. Vascular recanalizing techniques in interventional neuroradiology. J Neurol 1985;231:287–294.PubMedCrossRef
35.
Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976–982.PubMed
36.
del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986;17:595–607.PubMedCrossRef
37.
Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230:1289–1292.PubMedCrossRef
38.
Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke 1990;21:1589–1593.PubMedCrossRef
39.
Brott TG, Haley EC Jr., Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632–640.PubMedCrossRef
40.
Haley EC Jr., Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992;23:641–645.PubMedCrossRef
41.
von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992;23:646–652.CrossRef
42.
del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 992;32:78–86.
43.
Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.PubMedCrossRef
44.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
45.
Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by spect. Stroke 1998;29:429–432.PubMedCrossRef
46.
Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NIND t-PA stroke trial. Stroke 1997;28:2119–2125.
47.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109–2118.
48.
Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders And Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340:1781–1787.PubMedCrossRef
49.
Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology 2000;55:1649–1655.PubMed
50.
Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066–1070.PubMedCrossRef
51.
Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.PubMedCrossRef
52.
Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418–2424.PubMedCrossRef
53.
Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.PubMedCrossRef
54.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.PubMedCrossRef
55.
del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945–2948.PubMedCrossRef
56.
Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695–1703.PubMedCrossRef
57.
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre acute stroke trial--italy (MAST-I) group. Lancet 1995;346:1509–1514.
58.
Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group. JAMA 1996;276:961–966.PubMedCrossRef
59.
Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999;354:716–722.CrossRef
60.
Thomas GR, Thibodeaux H, Errett CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994;25:2072–2079.PubMedCrossRef
61.
Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TBK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001;32:748–752.PubMedCrossRef
62.
Haley EC Jr., Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607–612.PubMedCrossRef
63.
Haley EC Jr., Thompson JL, Grotta JC, et al. Phase IIb/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 41:707–711.
64.
Weaver WD. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. Eur Heart J1996;17(suppl E):14–20.PubMed
65.
Yenari MA, Lee LK, Beaulieu C, et al. Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke. J Stroke Cerebrovasc Dis 1998;7:179–186.PubMedCrossRef
66.
Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41–50.PubMed
67.
Sugg RM, Noser EA, Shaltoni HM, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006;27:769–773.PubMed
68.
Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537–543.PubMedCrossRef
69.
Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005;36:1241–1246.PubMedCrossRef
70.
Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73.PubMedCrossRef
71.
Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227–1231.PubMedCrossRef
72.
Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141–150.PubMedCrossRef
73.
H. Lundbeck A/S. Efficacy and safety study of desmoteplase to treat acute ischemic stroke (DIAS-3). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://​clinicaltrials.​gov/​show/​NCT00790920 NLM Identifier: NCT00790920. Accessed: November 14, 2010.
74.
Lundbeck H A/S. Efficacy and safety study of desmoteplase to treat acute ischemic stroke (DIAS-4). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://​clinicaltrials.​gov/​show/​NCT00856661 NLM Identifier: NCT00856661. Accessed: November 14, 2010.
75.
Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001;86:739–745.PubMed
76.
Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: Implications for stroke treatment. Stroke 2010;41:S45-S49.PubMedCrossRef
77.
Talecris Biotherapeutics. A safety and dose finding study of plasmin (human) administered into the middle cerebral artery of stroke patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://​clinicaltrials.​gov/​show/​NCT01014975 NLM Identifier: NCT01014975. Accessed: November 14, 2010.
78.
Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862–867.PubMed
79.
Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: Descriptive subtype analysis. Stroke 2011;42:102–106.PubMedCrossRef
Metadaten
Titel
Intravenous Thrombolytics for Ischemic Stroke
verfasst von
Andrew D. Barreto
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Neurotherapeutics / Ausgabe 3/2011
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-011-0049-x

Weitere Artikel der Ausgabe 3/2011

Neurotherapeutics 3/2011 Zur Ausgabe

Review

Vascular Imaging in Stroke: Comparative Analysis

Review

Prevention of Cardioembolic Stroke

Review

Stroke Epidemiology: Advancing Our Understanding of Disease Mechanism and Therapy

Abstracts

Abstracts from the ASENT 14th Annual Meeting

Review

Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications

Review

Brain Imaging in Stroke: Insight Beyond Diagnosis

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise